Medline Inc. (MDLN)
| Market Cap | 45.62B |
| Revenue (ttm) | 29.94B +12.1% |
| Net Income | 701.00M -45.3% |
| EPS | 0.80 +998.4% |
| Shares Out | 1.31B |
| PE Ratio | 43.61 |
| Forward PE | 23.60 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7,797,834 |
| Open | 34.84 |
| Previous Close | 34.66 |
| Day's Range | 34.47 - 35.30 |
| 52-Week Range | 31.49 - 50.88 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 44.60 (+28.53%) |
| Earnings Date | Aug 5, 2026 |
About MDLN
Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. It operates through two segments: Medline Brand and Supply Chain Solutions. The Medline Brand segment procures and manufactures products from three product categories include surgical solutions, front line care, and laboratory and diagnostics. Its front line care offers med-surg products for patient-facing needs, including wound care products, exam g... [Read more]
Financial Performance
In 2025, Medline's revenue was $28.43 billion, an increase of 11.47% compared to the previous year's $25.51 billion. Earnings were $1.16 billion, a decrease of -3.42%.
Financial StatementsAnalyst Summary
According to 27 analysts, the average rating for MDLN stock is "Buy." The 12-month stock price target is $44.6, which is an increase of 28.53% from the latest price.
News
Medline price target lowered to $43 from $45 at UBS
UBS analyst Kevin Caliendo lowered the firm’s price target on Medline (MDLN) to $43 from $45 and keeps a Buy rating on the shares.
Kaplan Fox Advises Investors of Medline Inc. (MDLN) to Contact the Firm Regarding a Securities Investigation
New York, New York--(Newsfile Corp. - September 24, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Medline Inc. ("Medline" or the "Company") (NASDAQ: MDLN...
$MDLN Stock Notification: Medline Inc. is Being Investigated for Securities Fraud after Product Quality Issues Disclosed – Investors are Alerted to Contact BFA Law
NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Medline Inc. (NASDAQ:MDLN) for potential securities fraud after its ...
Kaplan Fox Notifies Investors of Medline Inc. (MDLN) of a Securities Law Investigation
New York, New York--(Newsfile Corp. - September 22, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Medline Inc. ("Medline" or the "Company") (NASDAQ: MDLN...
Kaplan Fox Encourages Medline Inc. (MDLN) Investors to Contact the Firm Regarding a Securities Investigation
New York, New York--(Newsfile Corp. - September 18, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Medline Inc. ("Medline" or the "Company") (NASDAQ: MDLN...
Kaplan Fox Alerts Investors of Medline Inc. (MDLN) to a Securities Law Investigation
New York, New York--(Newsfile Corp. - September 16, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Medline Inc. ("Medline" or the "Company") (NASDAQ: MDLN...
Medline Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Strong top-line growth and market share gains were offset by external headwinds and operational investments, leading to a reduced EBITDA outlook. Strategic focus remains on brand conversion, automation, and expansion into new markets, with robust M&A capacity and ongoing technology innovation.
Kaplan Fox Announces an Investigation into Medline Inc. (MDLN) on Behalf of Investors
New York, New York--(Newsfile Corp. - September 14, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Medline Inc. ("Medline" or the "Company") (NASDAQ: MDLN...
Medline announces participation in the Morgan Stanley 24th Annual Global Healthcare Conference
NORTHFIELD, Ill., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (“Medline”) (Nasdaq: MDLN) today announced that Jim Boyle, chief executive officer, and Mike Drazin, chief financial officer, are sche...
Kaplan Fox Notifies Medline Inc. (MDLN) Investors of a Securities Investigation into the Company
New York, New York--(Newsfile Corp. - September 2, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Medline Inc. ("Medline" or the "Company") (NASDAQ: MDLN)...
Kaplan Fox Announces a Securities Investigation into Medline Inc. (MDLN) - Investors Encouraged to Contact the Firm
New York, New York--(Newsfile Corp. - August 24, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Medline Inc. ("Medline" or the "Company") (NASDAQ: MDLN). ...
Kaplan Fox Encourages Investors of Medline Inc. (MDLN) to Contact the Firm to Learn About Their Legal Rights
New York, New York--(Newsfile Corp. - August 21, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Medline Inc. ("Medline" or the "Company") (NASDAQ: MDLN). ...
Kaplan Fox is Investigating Medline Inc. (MDLN) for Potential Violations of the Federal Securities Laws
New York, New York--(Newsfile Corp. - August 19, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Medline Inc. ("Medline" or the "Company") (NASDAQ: MDLN). ...
Medline price target lowered to $46 from $53 at JPMorgan
JPMorgan lowered the firm’s price target on Medline (MDLN) to $46 from $53 and keeps an Overweight rating on the shares.
Medline price target lowered to $55 from $62 at Tigress Financial
Tigress Financial lowered the firm’s price target on Medline (MDLN) to $55 from $62 and keeps a Buy rating on the shares. The firm views the recent fire-related weakness in…
Medline price target lowered to $45 from $53 at TD Cowen
TD Cowen lowered the firm’s price target on Medline (MDLN) to $45 from $53 and keeps a Buy rating on the shares. The firm updated its model following Q2 results…
Medline price target lowered to $48 from $52 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Medline (MDLN) to $48 from $52 and keeps an Overweight rating on the shares.
Medline price target lowered to $42 from $45 at Bairdq
Baird analyst Eric Coldwell lowered the firm’s price target on Medline (MDLN) to $42 from $45 and keeps an Outperform rating on the shares. The firm updated its model following…
Medline price target lowered to $37 from $42 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Medline (MDLN) to $37 from $42 and keeps a Hold rating on the shares.
Medline price target lowered to $39 from $48 at Evercore ISI
Evercore ISI lowered the firm’s price target on Medline (MDLN) to $39 from $48 and keeps an Outperform rating on the shares.
Medline price target lowered to $47 from $56 at Truist
Truist analyst Jailendra Singh lowered the firm’s price target on Medline (MDLN) to $47 from $56 and keeps a Buy rating on the shares.
Medline price target lowered to $45 from $50 at Stifel
Stifel lowered the firm’s price target on Medline (MDLN) to $45 from $50 and keeps a Buy rating on the shares.
Medline price target lowered to $47 from $54 at BMO Capital
BMO Capital analyst Sean Dodge lowered the firm’s price target on Medline (MDLN) to $47 from $54 and keeps an Outperform rating on the shares.
Medline price target lowered to $48 from $53 at Mizuho
Mizuho lowered the firm’s price target on Medline (MDLN) to $48 from $53 and keeps an Outperform rating on the shares.
Medline price target lowered to $46 from $53 at RBC Capital
RBC Capital lowered the firm’s price target on Medline (MDLN) to $46 from $53 and keeps an Outperform rating on the shares.